Prices plus VAT plus shipping costs
Ready to ship today,
Delivery time appr. 5-8 days
- Order number: 7TM0247N-IC
- Content: 100 µl
- Host: Rabbit
The GHRH receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Growth Hormone-Releasing Hormone Receptor. It detects the canonical form of GHRHR as well as the amino-terminal splice variant SV1. It can be used to detect total GHRH receptors in Western blots independent of phosphorylation. The GHRHR antibody can also be used to isolate and enrich GHRH receptors from cell and tissue lysates. It also detects GHRHR in formalin-fixed, paraffin-embedded tissue sections by immunohistochemistry.
Alternative Names | GHRHR, Growth Hormone Releasing Hormone Receptor |
IUPHAR Target ID | 247 |
UniProt ID | Q02643 |
Western Blot (WB) | 1:1000 |
Immunohistochemistry (IHC) | 1:100 |
Species Reactivity | Human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Immunogen | A synthetic peptide presents distal end of carboxyl-terminal tail of human GHRHR |
Form | Liquid |
Purification | Antigen affinity chromatography |
Storage buffer | Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide |
Storage conditions | short-term 4°C, long-term -20°C |
Figure 1. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in breast carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (7TM0247N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, GHRH receptors were uniformly detected at the plasma membrane in breast carcinoma.
Figure 2. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in ovarian carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (77TM0247N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, GHRH receptors were detected predominantly at the level of plasma membrane in ovarian carcinoma.
Figure 3. Immunohistochemical identification of Growth Hormone-Releasing Hormone Receptor in prostate carcinoma. Sections were dewaxed, microwaved in citric acid, and incubated with anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (77TM0247N-IC) at a dilution of 1:100. Sections were then sequentially treated with biotinylated anti-rabbit IgG and avidin-biotin solution. Sections were then developed in 3,3-diaminobenzidine (DAB)-glucose oxidase and lightly counterstained with hematoxylin. Note, GHRH receptors were detected predominantly at the level of plasma membrane in prostate carcinoma.
Figure 4. Validation of the Growth Hormone-Releasing Hormone Receptor in pituitary adenoma. Growth hormone-producing pituitary adenoma was homogenated and immunoblotted using anti-GHRHR (Growth Hormone-Releasing Hormone Receptor) antibody (7TM0247N-IC) at a dilution of 1:1000 in presence (+) or absence (-) of 10 µg/ml peptide antigen. Note, absence of peptide leads to detection of GHRH receptors in pituitary adenoma but not in presence of peptide.